Zacks Research Expects Stronger Earnings for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities research analysts at Zacks Research lifted their Q1 2026 earnings per share estimates for Zimmer Biomet in a research note issued on Thursday, April 3rd. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings of $2.12 per share for the quarter, up from their prior forecast of $2.11. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet’s FY2026 earnings at $8.80 EPS and Q1 2027 earnings at $2.25 EPS.

A number of other equities analysts have also commented on ZBH. Raymond James cut their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Truist Financial restated a “hold” rating and set a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their target price for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. JMP Securities reissued a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Barclays cut their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Trading Down 2.5 %

NYSE ZBH opened at $104.65 on Monday. The company’s fifty day simple moving average is $107.16 and its 200-day simple moving average is $107.22. The stock has a market cap of $20.83 billion, a P/E ratio of 23.52, a PEG ratio of 1.95 and a beta of 0.84. Zimmer Biomet has a 52 week low of $97.69 and a 52 week high of $129.50. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the company posted $2.20 EPS.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.95% of the company’s stock.

Institutional Investors Weigh In On Zimmer Biomet

Several large investors have recently made changes to their positions in the company. Stonebridge Financial Group LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter worth approximately $25,000. Dunhill Financial LLC boosted its position in Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 218 shares during the period. Menard Financial Group LLC bought a new position in shares of Zimmer Biomet in the fourth quarter worth $30,000. Accredited Wealth Management LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter valued at $36,000. Finally, Kentucky Trust Co bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at about $39,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.